Q-omics provides the consensus-scored STRADB profile across patient tissues and cancer cell-line models. STRADB expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, STRADB is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, STRADB RNA expression shows 19,747 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and THCA as cancer lineages where STRADB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STRADB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STRADB survival associations across molecular data types. STRADB RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STRADB RNA expression–survival associations across cancer types. High STRADB expression shows unfavorable associations in UVM, KIRP, ACC, LIHC and DLBC, but favorable associations in THCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for STRADB RNA expression.
This table summarizes STRADB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for STRADB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STRADB shows lower tumor expression in KICH, COAD and BRCA and higher tumor expression in THCA, BLCA and UCEC. The THCA box plot shows higher STRADB RNA expression in tumor versus normal tissue (log2 FC = +0.872, t-test p < 0.001).
This table shows molecular features associated with STRADB in patient tissues and cancer cell lines. In patient samples, STRADB shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, STRADB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and OVARY.
